PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise

Core Insights - Penumbra, Inc. reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18, exceeding the Zacks Consensus Estimate by 5.36% and showing a significant increase from 85 cents in the same quarter last year [1] - The company’s revenues for the quarter reached $385.4 million, reflecting a year-over-year increase of 22.1% and surpassing the Zacks Consensus Estimate by 6.74% [2] - Penumbra announced a definitive agreement to be acquired by Boston Scientific, valuing the company at approximately $14.5 billion, leading to the cessation of financial guidance for 2026 [9] Revenue Performance - Total revenues for the fourth quarter were $385.4 million, up 22.1% year over year, with a full-year revenue of $1.40 billion, marking a 17.5% increase from the previous year [2] - U.S. revenues accounted for $299.1 million (77.6% of total revenues), increasing by 20.6% year over year, while international revenues rose by 27.7% to $86.3 million [3] - Thrombectomy product sales reached $254.7 million, up 15.7%, and Embolization and Access products totaled $130.7 million, up 22.1% [4] Margin Analysis - Gross profit for the quarter improved by 24.4% to $262.1 million, with a gross margin expansion of 123 basis points to 68% despite a 17.6% increase in the cost of revenues [5] - Selling, general and administrative expenses rose by 22.4% to $181.1 million, while research and development expenses increased by 8.9% to $21.8 million [6] - Adjusted operating profit was $59.2 million, up from $42.8 million in the previous year, with an adjusted operating margin expansion of 181 basis points to 13.4% [6] Financial Position - At the end of the fourth quarter, Penumbra had cash and marketable investments totaling $544.8 million, an increase from $340.1 million at the end of 2024 [7] Clinical Developments - The company announced results from the STORM-PE trial, demonstrating that mechanical thrombectomy with anticoagulation significantly reduced right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism [11]